Deals In Depth: October 2022
Executive Summary
Two $1bn+ alliances were penned in October. Financing reached $7.7bn in biopharma, $636m in device, and $140m in diagnostics.
You may also be interested in...
Minute Insight: Thermo Fisher Buys Diagnostics Company The Binding Site For $2.6Bn
Birmingham, UK-based The Binding Site and its 1,100 employees will now fall under Thermo Fisher’s expanding umbrella.
Zymeworks Deal Expands Jazz’s Potential Oncology Presence
The deal focuses on the HER2-targeting bispecific antibody zanidatamab, in development for multiple solid tumor indications expressing HER2.
Deals in Depth: March 2024
Two $1bn+ alliances were penned in March. In the top alliance by deal value, Merus NV will use its Triclonics anitbody platform to discover new dual tumor-associated antigens targeting trispecific antibodies for Gilead Sciences. Merus will lead early-stage research activities for two programs, with an option to pursue a third. Gilead will have the right to license programs developed under the collaboration after the completion of select research activities. If Gilead exercises its option to license any such program from the collaboration, Gilead will be responsible for additional research, development and commercialization activities for such program. The deal could be worth up to $1.5bn for Merus.